Listing 13.20 Pancreatic Cancer in 2026

Pancreatic cancer is one of the deadliest cancers in the United States. The American Cancer Society projects 66,440 new pancreatic cancer diagnoses (34,530 men, 31,910 women) and 51,750 deaths in 2026. Overall 5-year survival remains around 13%, with stage IV metastatic disease at about 3%. Median survival for metastatic pancreatic adenocarcinoma runs 6-12 months even with modern chemotherapy. About 80% of patients present with locally advanced or metastatic disease at diagnosis because the pancreas is deep and symptoms are vague until late.

SSA Listing 13.20 has a dedicated section for pancreatic cancer with three paragraphs that together cover essentially every clinical presentation. Adenocarcinoma at any stage meets the listing. Islet cell (neuroendocrine) carcinoma with progression meets. Recurrent adenocarcinoma meets. This walkthrough covers the paragraph structure, the CAL fast-track, and how modern chemotherapy regimens shape treatment residuals for the small number of patients who reach the 3-year mark.

The listing text

Paragraph A: Adenocarcinoma

Adenocarcinoma of the pancreas qualifies at any stage. Ductal adenocarcinoma (85-90% of pancreatic cancer) automatically meets the listing regardless of stage, resectability, or treatment plan. This includes:

• Stage I resectable disease
• Stage II borderline resectable disease
• Stage III locally advanced unresectable disease
• Stage IV metastatic disease

The rationale is clear: pancreatic adenocarcinoma has a 5-year survival of about 13% overall and less than 5% for stage III-IV. Even patients with resectable stage I disease have 5-year survival around 30-40%. The disease is fatal often enough that automatic qualification is warranted.

Paragraph B: Islet cell (neuroendocrine) carcinoma with progression

Pancreatic neuroendocrine tumors (pNETs), historically called islet cell tumors, are a different disease from adenocarcinoma. About 5% of pancreatic cancers are neuroendocrine. Well-differentiated pNETs can behave indolently for years. Poorly differentiated neuroendocrine carcinomas behave like aggressive adenocarcinoma.

Paragraph B requires "clinical evidence of progression" - not just presence of the tumor. Progression can be:

• Growth on imaging
• New metastatic sites
• Rising tumor markers (chromogranin A, pancreatic polypeptide)
• Worsening functional hormone syndromes (insulinoma, gastrinoma, VIPoma, glucagonoma, somatostatinoma)
• Failure of prior therapy

Small (under 2 cm), non-functional, well-differentiated pNETs may not meet 13.20B without progression evidence. These are often watched with surveillance imaging.

Paragraph C: Recurrent adenocarcinoma

Recurrent pancreatic adenocarcinoma after prior treatment (resection, chemotherapy, radiation) qualifies under Paragraph C. Recurrence rates after Whipple resection are high (60-80% within 2 years), and recurrent disease has universally poor prognosis.

Diagnostic evidence required

SSA requires objective medical evidence:

• Pathology report from EUS-guided fine needle aspiration (FNA), CT-guided biopsy, or surgical specimen with:
  • Histologic type (adenocarcinoma, neuroendocrine, acinar cell, etc.)
  • Grade (well/moderately/poorly differentiated)
  • Margin status if resected (R0/R1/R2)
  • Lymph node involvement
  • Perineural invasion
  • Lymphovascular invasion
• Staging imaging: CT abdomen/pelvis with pancreatic protocol, MRI abdomen with MRCP, PET-CT, chest CT for distant metastases
• Serum tumor markers: CA 19-9 (elevated in 80%+ of adenocarcinoma), CEA, chromogranin A for neuroendocrine
• Germline BRCA testing - 4-7% of pancreatic adenocarcinoma has germline BRCA1/2 mutations. Positive germline testing changes treatment (olaparib eligibility per POLO trial) and family screening.
• Somatic tumor testing: KRAS (present in 90%+, drives targeted therapy consideration), BRCA1/2, PALB2, MSI status, NTRK fusions, HER2
• Endoscopic ultrasound (EUS) report with tumor size, vascular involvement, nodal involvement
• Nutritional status: albumin, prealbumin, weight loss documentation (often 10-20% body weight lost pre-diagnosis)

The Compassionate Allowance overlay

Pancreatic cancer is on the CAL list. All pancreatic adenocarcinoma cases automatically flag for expedited processing, targeting 14-30 days for initial decision. The rationale is that pancreatic cancer often has median survival under a year, so waiting the typical 3-6 months for standard SSDI review would fail many patients.

Islet cell (neuroendocrine) tumors are on CAL only with distant metastases. Non-metastatic pNETs go through standard SSDI processing.

Pancreatic cancer also frequently qualifies as Terminal Illness (TERI) when documented life expectancy is under 6 months.

Modern treatment residuals for the CDR

The 3-year remission rule under 13.00H1 applies in theory. In practice, few pancreatic cancer patients reach the 3-year mark. For those who do (typically stage I-II resected patients with negative margins and effective adjuvant therapy), treatment residuals are extensive.

FOLFIRINOX chemotherapy

Standard for fit patients (ECOG 0-1, no significant comorbidities) with locally advanced or metastatic adenocarcinoma. Combination of 5-FU, leucovorin, irinotecan, and oxaliplatin. Also used in adjuvant setting per PRODIGE 24 trial (modified FOLFIRINOX improved 5-year survival from 21% to 43% post-Whipple). Toxicities:

• Oxaliplatin-induced peripheral neuropathy (60-70% at 12+ months, can be permanent)
• Chemotherapy-induced fatigue (universal, often lasting years)
• Neutropenia, thrombocytopenia, anemia
• Mucositis, diarrhea
• Irinotecan-induced acute cholinergic syndrome
• Chronic diarrhea from irinotecan
• Cognitive changes ("chemo brain") persisting 6-24 months

Gemcitabine + nab-paclitaxel (gem/abraxane)

Alternative first-line for patients who cannot tolerate FOLFIRINOX. Also used as first-line for less fit patients. Toxicities:

• Nab-paclitaxel-induced peripheral neuropathy (30-40%)
• Fatigue
• Neutropenia
• Peripheral edema
• Alopecia

NALIRIFOX (NAPOLI-3 2023)

Liposomal irinotecan + oxaliplatin + 5-FU/leucovorin. FDA-approved 2024 for first-line metastatic pancreatic adenocarcinoma based on NAPOLI-3 trial showing improved overall survival vs gem/nab-paclitaxel. Toxicities similar to FOLFIRINOX plus liposomal irinotecan-specific effects.

Olaparib maintenance (POLO trial)

PARP inhibitor for germline BRCA1/2-mutated metastatic pancreatic adenocarcinoma after platinum-based chemotherapy without progression. POLO trial (2019) showed doubling of progression-free survival. Toxicities:

• Fatigue
• Nausea
• Anemia
• Risk of MDS/AML with long-term use (1-2%)

Whipple procedure (pancreaticoduodenectomy)

Standard curative-intent surgery for pancreatic head tumors. Removes head of pancreas, duodenum, gallbladder, common bile duct, and part of stomach in classic Whipple (or preserves pylorus in PPPD). Reconstruction with pancreaticojejunostomy, hepaticojejunostomy, and duodenojejunostomy or gastrojejunostomy. Residuals include:

• Postoperative pancreatic fistula (10-25%)
• Delayed gastric emptying (15-30%)
• Pancreatic exocrine insufficiency requiring pancreatic enzyme replacement (nearly universal)
• Pancreatogenic diabetes (30-50% at 3+ years)
• Weight loss and malnutrition
• Chronic diarrhea/steatorrhea
• Bile reflux gastritis
• Marginal ulcer
• Cholangitis from bilioenteric anastomosis
• Long-term small bowel adhesions

These qualify under 5.00 digestive listings (5.08 short bowel or weight loss due to digestive disorders) and 9.00 endocrine (diabetes) at CDR.

Distal pancreatectomy + splenectomy

For tumors in the body or tail of the pancreas. Residuals include splenectomy-related permanent asplenia (encapsulated organism infection risk), pancreatogenic diabetes (20-30% at 3 years, higher if larger resection), pancreatic exocrine insufficiency, chronic wound issues.

Total pancreatectomy

Rare, reserved for multifocal disease or extensive intraductal papillary mucinous neoplasm (IPMN). Results in complete pancreatic exocrine insufficiency (100% require enzyme replacement) and brittle pancreatogenic diabetes (100%, difficult to manage with wide glucose swings due to absent glucagon response). These profoundly disable patients even at CDR.

Worked case examples

Case 1: Michael, 68, California, stage IV pancreatic adenocarcinoma with liver metastases

Michael presented with 3 months of progressive back pain, 25 lb weight loss, and painless jaundice in February 2026. CT abdomen showed 4 cm pancreatic head mass with biliary obstruction and 5 liver lesions. EUS-FNA confirmed pancreatic ductal adenocarcinoma. CA 19-9 3,200. Stage IV M1c.

SSDI application filed February 2026. CAL for pancreatic cancer triggered. Approved 9 days at California DDS. Endoscopic biliary stent placed for jaundice. Started FOLFIRINOX. Partial response at 3 months. Progressed at 8 months, switched to second-line NALIRIFOX. Died December 2026, 10 months post-diagnosis.

Case 2: Sarah, 58, Massachusetts, germline BRCA2 metastatic pancreatic adenocarcinoma with olaparib maintenance

Sarah had a family history of breast and ovarian cancer (mother, sister). Presented with epigastric pain and weight loss in January 2026. CT: 3 cm pancreatic body mass, 3 liver mets. EUS-FNA: adenocarcinoma. Germline testing: BRCA2 pathogenic mutation.

SSDI application filed February 2026. CAL for pancreatic cancer triggered. Approved 12 days at Massachusetts DDS. Started FOLFIRINOX with response at 4 months. Transitioned to olaparib maintenance per POLO trial. Ongoing response at 12 months. Represents the exceptional favorable prognosis subset with germline BRCA that may reach 3+ year survival, with chronic olaparib toxicities (fatigue, anemia) at future CDR.

Case 3: Robert, 71, Texas, stage IB pancreatic head adenocarcinoma post-Whipple

Robert presented with painless jaundice and pruritus in March 2026. CT: 2.8 cm pancreatic head mass without vascular involvement or metastases. Resectable disease. EUS-FNA: adenocarcinoma. Stage IB (T2N0M0).

SSDI application filed April 2026. CAL for pancreatic cancer triggered. Approved 14 days at Texas DDS. Underwent classic Whipple with negative margins (R0). Adjuvant modified FOLFIRINOX x 12 cycles per PRODIGE 24. Developed post-operative pancreatic fistula managed with drain, pancreatogenic diabetes at 6 months requiring insulin, and grade 2 oxaliplatin peripheral neuropathy. At 3-year CDR (2029), no evidence of recurrence, but pancreatogenic diabetes and severe peripheral neuropathy support continued disability under 9.00 and 11.00 listings.

What to file with your application

1. Pathology report confirming pancreatic cancer histology
2. Staging imaging: CT abdomen/pelvis with pancreatic protocol, PET-CT, MRI/MRCP
3. CA 19-9 and CEA levels
4. Chromogranin A if pNET suspected
5. Germline BRCA testing results
6. Somatic tumor testing (KRAS, BRCA1/2, PALB2, MSI, NTRK, HER2)
7. Oncology consultation notes with stage assignment and treatment plan
8. Weight loss and nutritional status documentation
9. Post-operative pathology if resected (margins, nodes)
10. Adjuvant/palliative treatment plan and any complications

Related reading

Full section walkthrough: Section 13.00 cancer basics. Related listing: 5.12 pancreas transplantation for pNET or extensive pancreatic surgery cases. Other cancer listings: 13.18 colorectal, 13.10 breast, 13.15 mesothelioma, 13.13 CNS/brain.

Frequently asked questions

Next steps

If you were diagnosed with pancreatic cancer, file for SSDI immediately after pathology confirmation. The CAL fast-track will process your claim in days to weeks, not months. Do not wait until the treatment plan is finalized.